# OnCo record oncolytic-virus (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/oncolytic-virus/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "oncolytic-virus" ;
  schema:name "Oncolytic viruses"@en ;
  schema:alternateName "Oncolytic virus"@en, "Oncolytic virotherapy"@en ;
  schema:description "Viruses engineered to infect and burst cancer cells while leaving normal cells alone, and to alert the immune system in the process."@en ;
  schema:url <https://onco.cc/technologies/oncolytic-virus/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Oncolytic_virus> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1560099> ;
  schema:citation <https://en.wikipedia.org/wiki/Oncolytic_virus>, <https://onco.cc/virotherapy/> ;
  onco:status "approved" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:drugs <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/drugs/talimogene-laherparepvec/>, <https://onco.cc/drugs/nadofaragene-firadenovec/>, <https://onco.cc/drugs/cretostimogene/>, <https://onco.cc/drugs/h101-oncolytic-adenovirus/>, <https://onco.cc/drugs/olvimulogene-nanivacirepvec/>, <https://onco.cc/drugs/aglatimagene-besadenovec/> ;
  onco:companies <https://onco.cc/companies/replimune/>, <https://onco.cc/companies/amgen/>, <https://onco.cc/companies/candel-therapeutics/>, <https://onco.cc/companies/humane-genomics/>, <https://onco.cc/companies/kopra-bio/>, <https://onco.cc/companies/transgene/>, <https://onco.cc/companies/minuteman-therapeutics/> ;
  onco:people <https://onco.cc/people/robert-martuza/>, <https://onco.cc/people/stephen-russell/>, <https://onco.cc/people/john-bell/>, <https://onco.cc/people/tomoki-todo/>, <https://onco.cc/people/beata-halassy/>, <https://onco.cc/people/dubravko-forcic/>, <https://onco.cc/people/howard-kaufman/>, <https://onco.cc/people/evanthia-galanis/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-stojdl-vsv-interferon-defect-natmed-2000/>, <https://onco.cc/key-papers/paper-coffey-reovirus-ras-science-1998/>, <https://onco.cc/key-papers/paper-martuza-engineered-hsv-glioma-science-1991/>, <https://onco.cc/key-papers/paper-bischoff-onyx-015-science-1996/>, <https://onco.cc/key-papers/paper-kelly-russell-oncolytic-history-moltherapy-2007/>, <https://onco.cc/key-papers/paper-russell-peng-bell-oncolytic-virotherapy-natbiotech-2012/>, <https://onco.cc/key-papers/paper-shalhout-oncolytic-progress-challenges-natrevclinonc-2023/>, <https://onco.cc/key-papers/paper-andtbacka-optim-talimogene-jco-2015/>, <https://onco.cc/key-papers/paper-todo-g47delta-glioblastoma-natmed-2022/>, <https://onco.cc/key-papers/paper-xia-h101-head-neck-aizheng-2004/>, <https://onco.cc/key-papers/paper-wong-ignyte-rp1-nivolumab-jco-2025/>, <https://onco.cc/key-papers/paper-russell-mv-nis-myeloma-mayo-2014/>, <https://onco.cc/key-papers/paper-cloughesy-toca5-glioma-jamaoncol-2020/>, <https://onco.cc/key-papers/paper-abou-alfa-phocus-pexa-vec-liver-cancer-2024/>, <https://onco.cc/key-papers/paper-hietanen-rigvir-echovirus-viruses-2022/>, <https://onco.cc/key-papers/paper-bourgeois-daigneault-neoadjuvant-ovt-tnbc-scitranslmed-2018/>, <https://onco.cc/key-papers/paper-halassy-self-experiment-ovt-vaccines-2024/>, <https://onco.cc/key-papers/paper-pugh-self-experimentation-publication-jme-2026/> ;
  onco:journals <https://onco.cc/journals/cancer-gene-therapy/> ;
  onco:dependsOn <https://onco.cc/technologies/viral-vector-manufacturing/> .